Dr. Pius S. Hornstein Appointed President of Sanofi China

Today (March 1), Sanofi officially announced that Dr. Pius S. Hornstein, PhD, has assumed the role of General Manager of Sanofi China and President of Sanofi China, effective immediately. He is based in Shanghai and reports directly to Olivier Charmeil, Executive Vice President of Sanofi and Head of the Global Business Unit for China and Emerging Markets.

Mr. Jean-Christophe Pointeau, former President of Sanofi China, has been appointed as the Head of Sanofi Genzyme Europe. He delivered outstanding results for Sanofi China over the past four years. Since January this year, Mr. Pointeau has worked closely with Mr. Enrico Tealdi to ensure a smooth handover and a successful transition in the important Chinese market.

“China has become Sanofi’s second-largest market, with growth reaching as high as 12.7% in 2018. Based on our long-term contributions to the Chinese market and the acceleration driven by innovation, I firmly believe that CEO Olivier Bogillot will lead Sanofi China to even greater success,” said Xia Liwei. “On January 1 this year, Sanofi officially launched its Global Business Unit for China and Emerging Markets, focusing on the unique characteristics and growth opportunities of emerging markets. Sanofi will leverage emerging markets as its primary growth engine and further strengthen its investments in these regions, particularly in the Chinese market.”

Dr. He Enting stated, “Leading the China team is a tremendous honor and responsibility for me. The Chinese pharmaceutical market is undergoing rapid transformation. My top priority is to accelerate the introduction of innovative products into China, while focusing on the development of Sanofi China’s strong talent team.”

He further stated that Sanofi will uphold its commitment to “Rooted in China, Serving China,” adhere to the highest ethical standards, and make more innovative medicines and vaccines accessible to Chinese patients and the public, thereby further supporting the “Healthy China 2030” strategy. “We will continue to grow steadily and maintain our industry leadership as always. Together with all Sanofi China employees, I am committed to innovation, collaboration, and dedication, sustaining our growth momentum to establish Sanofi as one of the leading pharmaceutical and healthcare companies in China. I am filled with confidence and passion for this endeavor.”

For the past four years, He Enting has served as President of Sanofi Brazil. He joined Sanofi in 1998, starting as a Product Manager, and has held a series of key positions within the company over the years, spanning marketing, sales management, and other global strategic management roles. He played a pivotal role in advocating for the inclusion of anticoagulants in the World Health Organization’s (WHO) Model List of Essential Medicines. Mr. He holds a Master’s degree in Pharmacy and graduated with honors from the University of Basel in Switzerland.MedicineResearch Doctorate.

As one of the first multinational pharmaceutical companies to enter China, Sanofi holds a leading position in the fields of chronic diseases, rare diseases, and vaccines. Sanofi has introduced more than 40 high-quality innovative drugs and vaccine products to the Chinese market, with its diversified treatment solutions covering seven of the top ten fatal diseases in China. Looking ahead, Sanofi China is committed to accelerating innovation, with an expected launch of 16 new products and indications in China by 2025.

Source: Jian Shi Ju